Live
Compounded infliximab (Ref: 2020/S 209-511772)
Background
The framework agreement is for the provision of compounded infliximab. This entails suppliers sourcing the product from the manufacturer and compounding it, under aseptic conditions, into an appropriate infusion device and supplying to the trust ready for use by a clinician. The framework is split into three lots for the three available brands of infliximab; Inflectra, Remicade and Remsima respectively.
Start date
02/01/2021
End date
01/02/2025
Contract type
Framework Agreement
List of suppliers and awarded lots
Portsmouth, Quantum, ITH, Baxter, Qualasept Ltd (Bath ASU).
Access the framework documents
If you have a login to our sharepoint, you can access the framework documents below.
Not a member or don't have a login? Please email [email protected] to request access to framework documentation.